Previous 10 | Next 10 |
2023-12-01 13:56:32 ET Summary Today's news that Pfizer Inc.'s twice-daily oral weight loss drug will be discontinued due to safety concerns has dropped the share price to a new low. The company has struggled all year as its COVID franchise has disintegrated after contributing ~$1...
2023-12-01 12:50:00 ET More on Pfizer, Rhythm Pharma etc. Pfizer Inc. (PFE) 6th Annual Evercore ISI HealthCONx Conference (Transcript) Pfizer Is A Fantastic Buy And So Are These 9%-Yielding Blue Chips Rhythm Pharmaceuticals: Major Catalysts Due For Weight Loss Specia...
2023-12-01 11:09:29 ET More on Novo Nordisk Novo Nordisk: Plenty More Room To Run Despite Its Hefty Valuation Novo Nordisk: Massive Reality Check Awaits Greedy Investors Novo Nordisk: Healthy Gains Ahead, EPS Growth Seen, Technical Strength Novo Nordisk sues ...
2023-12-01 10:15:12 ET More on Altimmune, Eli Lilly, etc. Bubble Warning: Unrealistic Growth Priced In And Multiple Risk Factors For Eli Lilly Eli Lilly and Company (LLY) Presents at 6th Evercore ISI HealthCONx Conference (Transcript) Novo Nordisk: Plenty More Room T...
2023-12-01 09:45:00 ET Eli Lilly (NYSE: LLY) is a top growth stock to own. The business is worth $560 billion, and that valuation is likely to get bigger in the years ahead. You might be tempted to buy the stock for the company's well-diversified product portfolio or perhaps for Zep...
2023-12-01 07:58:04 ET Eli Lilly (NYSE: LLY) and Novo Nordisk NYSE: NVO) stock prices have been some of the hottest names in Wall Street. NVO has soared by over 48% this year while LLY has surged by over 61%. In total, these companies are now valued at almost $1 trillion. Eli Lilly ...
2023-12-01 07:14:35 ET Pfizer ( NYSE: PFE ) announced on Friday that its investigating weight-loss pill, danuglipron, met its primary endpoint in a Phase 2b clinical trial evaluating its efficacy and safety of in adults with obesity and without type 2 diabetes. Danuglipron, ...
2023-11-30 19:47:33 ET Summary Duquesne Family Office's 13F portfolio value decreased by 3% to $2.79B in Q3 2023. The largest holdings in the portfolio are Nvidia, Coupang, Microsoft, Eli Lilly, and Teck Resources, making up 53% of the portfolio. New stakes include Alphabet, V...
2023-11-30 16:30:09 ET Summary Medtronic's recent earnings report has boosted investor confidence, suggesting the worst may be over for the company. The impact of the weight loss drugs on Medtronic's long-term growth prospects is expected to be limited and could be overstated. ...
2023-11-30 11:00:00 ET Summary The weight loss drug, Zepbound, faces immense competition and may lose its battle once a pill form of weight loss drug becomes available. The company has a surprisingly low diversification of revenues. Revenues are susceptible to upcoming LOEs. T...
News, Short Squeeze, Breakout and More Instantly...
2024-07-30 07:07:00 ET If your portfolio doesn't have exposure to the biopharma businesses pursuing the development of weight loss medicines, it might be time to consider changing that situation. With an influx of new drugs for sale, and many competitors looking to secure their share of the...
2024-07-30 05:48:00 ET Going into 2024, DexCom 's (NASDAQ: DXCM) shares were up a whopping 14 times over the last 10 years. The company's continuous glucose monitoring (CGM) devices enjoyed tremendous demand from individuals with diabetes. However, last week was the worst for De...
2024-07-29 15:13:21 ET Eli Lilly & Co (NYSE: LLY) has recently experienced a dramatic $123 billion decline in market value. This significant drop follows positive developments from competitors, notably Viking Therapeutics Inc and Roche Holding AG, who made announcements regarding th...